(Reuters) -McKesson said on Thursday it will restructure its operations into four main segments from the current quarter as the U.S. drug distributor aims to focus on high-margin businesses such as cancer medicines to boost growth.

The restructuring will reflect how CEO Brian Tyler will allocate resources and assess performance going forward, but does not affect previously issued financial statements or historical earnings per share, the company said.

“This updated reporting structure reflects a strategic evolution of our business – accelerating growth in the high-margin areas of oncology, multispecialty, and biopharma services,” Chief Financial Officer Britt Vitalone said in a statement.

Starting this quarter, its second in fiscal 2026, the Texas-based firm will reorganize into North A

See Full Page